KR102489143B1 - 재조합 ｈｃｇ를 포함하는 약학 조제물 - Google Patents

재조합 ｈｃｇ를 포함하는 약학 조제물 Download PDF

Info

Publication number
KR102489143B1
KR102489143B1 KR1020217037028A KR20217037028A KR102489143B1 KR 102489143 B1 KR102489143 B1 KR 102489143B1 KR 1020217037028 A KR1020217037028 A KR 1020217037028A KR 20217037028 A KR20217037028 A KR 20217037028A KR 102489143 B1 KR102489143 B1 KR 102489143B1
Authority
KR
South Korea
Prior art keywords
hcg
mol
rhcg
leu
sialylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217037028A
Other languages
English (en)
Korean (ko)
Other versions
KR20210141771A (ko
Inventor
이안 코팅햄
다니엘 플락신
리차드 보이드 화이트
Original Assignee
훼링 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훼링 비.브이. filed Critical 훼링 비.브이.
Priority to KR1020237001308A priority Critical patent/KR20230012104A/ko
Publication of KR20210141771A publication Critical patent/KR20210141771A/ko
Application granted granted Critical
Publication of KR102489143B1 publication Critical patent/KR102489143B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217037028A 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물 Active KR102489143B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237001308A KR20230012104A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
EP09252360.4 2009-10-05
KR1020217003233A KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003233A Division KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001308A Division KR20230012104A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Publications (2)

Publication Number Publication Date
KR20210141771A KR20210141771A (ko) 2021-11-23
KR102489143B1 true KR102489143B1 (ko) 2023-01-13

Family

ID=41471027

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020217037028A Active KR102489143B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020237001308A Pending KR20230012104A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020177034392A Withdrawn KR20170133531A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020197016021A Active KR102213154B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020127008827A Active KR101804479B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020217003233A Ceased KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020197007226A Expired - Fee Related KR101987982B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020237001308A Pending KR20230012104A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020177034392A Withdrawn KR20170133531A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020197016021A Active KR102213154B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020127008827A Active KR101804479B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020217003233A Ceased KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020197007226A Expired - Fee Related KR101987982B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Country Status (25)

Country Link
US (5) US8975226B2 (enExample)
EP (2) EP2486051B1 (enExample)
JP (6) JP6176924B2 (enExample)
KR (7) KR102489143B1 (enExample)
CN (1) CN107050434B (enExample)
AR (2) AR079876A1 (enExample)
AU (1) AU2010304922B2 (enExample)
BR (1) BR112012007990A2 (enExample)
CA (1) CA2776790A1 (enExample)
DK (1) DK2486051T3 (enExample)
ES (2) ES3036152T3 (enExample)
HR (1) HRP20200941T1 (enExample)
HU (1) HUE050793T2 (enExample)
IL (3) IL218548A (enExample)
IN (1) IN2012DN02073A (enExample)
JO (1) JOP20200039A1 (enExample)
LT (1) LT2486051T (enExample)
MX (1) MX2012003951A (enExample)
PL (1) PL2486051T3 (enExample)
PT (1) PT2486051T (enExample)
RS (1) RS60413B1 (enExample)
RU (2) RU2724528C2 (enExample)
SI (1) SI2486051T1 (enExample)
TW (2) TWI532495B (enExample)
WO (1) WO2011042688A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) * 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
SG10201704774VA (en) 2012-12-10 2017-07-28 Seikagaku Kogyo Co Ltd Novel recombinant factor c and method for producing the same, and method for measuring endotoxin
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
EA034022B1 (ru) * 2015-04-24 2019-12-19 Ферринг Б.В. Способ получения гонадотропина
MX381279B (es) 2015-06-26 2025-03-12 Ferring Bv Métodos de purificación y/o inactivación viral.
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226681A1 (en) 2004-02-13 2008-09-18 Glycotope Gmbh Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
ES2166841T3 (es) * 1995-03-21 2002-05-01 Applied Research Systems Formulaciones liquidas de hcg.
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
BR9810478A (pt) 1997-06-25 2000-09-12 Applied Research Systems Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP4588960B2 (ja) 2000-02-22 2010-12-01 メルク セローノ ソシエテ アノニム ｈＣＧの精製方法及び本法により精製した組換えｈＣＧ
EP1425032A2 (en) 2001-09-12 2004-06-09 Applied Research Systems ARS Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
UA87433C2 (ru) * 2001-10-22 2009-07-27 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Гонадотропины для стимулирования фолликулогенеза
CN100347306C (zh) * 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
NZ542586A (en) * 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
EP1654353B1 (en) * 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
EP1711834B1 (en) 2004-02-04 2010-08-04 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
DE112006002122B4 (de) * 2005-08-15 2016-09-22 Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (en) * 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226681A1 (en) 2004-02-13 2008-09-18 Glycotope Gmbh Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production

Also Published As

Publication number Publication date
IL218548A (en) 2017-03-30
HRP20200941T1 (hr) 2020-09-18
JP6310440B2 (ja) 2018-04-11
JOP20200039A1 (ar) 2022-10-30
JP6580104B2 (ja) 2019-09-25
RU2016118236A (ru) 2018-10-29
ES3036152T3 (en) 2025-09-15
EP3611185A1 (en) 2020-02-19
US12234272B2 (en) 2025-02-25
JP2016074680A (ja) 2016-05-12
KR20170133531A (ko) 2017-12-05
CN107050434B (zh) 2021-07-27
IL218548A0 (en) 2012-05-31
RU2588650C2 (ru) 2016-07-10
US20220340634A1 (en) 2022-10-27
LT2486051T (lt) 2020-07-10
JP2018076296A (ja) 2018-05-17
CA2776790A1 (en) 2011-04-14
JP7292153B2 (ja) 2023-06-16
KR20210141771A (ko) 2021-11-23
KR20230012104A (ko) 2023-01-25
JP7196244B2 (ja) 2022-12-26
KR101804479B1 (ko) 2017-12-05
RS60413B1 (sr) 2020-07-31
EP3611185B1 (en) 2025-04-30
IN2012DN02073A (enExample) 2015-08-21
DK2486051T3 (da) 2020-06-22
AU2010304922A1 (en) 2012-03-29
US20180030107A1 (en) 2018-02-01
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
PL2486051T3 (pl) 2020-09-07
US20130023476A1 (en) 2013-01-24
US20140249082A1 (en) 2014-09-04
ES2798258T3 (es) 2020-12-10
RU2016118236A3 (enExample) 2019-09-18
HUE050793T2 (hu) 2021-01-28
US9676835B2 (en) 2017-06-13
IL250733A0 (en) 2017-04-30
KR102213154B1 (ko) 2021-02-05
BR112012007990A2 (pt) 2017-07-25
EP2486051A1 (en) 2012-08-15
KR20190028823A (ko) 2019-03-19
IL267556A (en) 2019-08-29
JP2013506708A (ja) 2013-02-28
KR20190067256A (ko) 2019-06-14
JP6176924B2 (ja) 2017-08-09
TWI532495B (zh) 2016-05-11
AR079876A1 (es) 2012-02-29
KR20210014767A (ko) 2021-02-09
CN107050434A (zh) 2017-08-18
JP2021176867A (ja) 2021-11-11
US11292824B2 (en) 2022-04-05
US10526390B2 (en) 2020-01-07
TW201113030A (en) 2011-04-16
RU2012112907A (ru) 2013-11-10
MX2012003951A (es) 2012-05-29
AR125991A2 (es) 2023-08-30
US8975226B2 (en) 2015-03-10
PT2486051T (pt) 2020-06-17
JP2023075144A (ja) 2023-05-30
WO2011042688A1 (en) 2011-04-14
SI2486051T1 (sl) 2020-08-31
CN102549011A (zh) 2012-07-04
RU2724528C2 (ru) 2020-06-23
TW201632198A (zh) 2016-09-16
US20200247863A1 (en) 2020-08-06
AU2010304922B2 (en) 2014-11-06
IL250733B (en) 2019-07-31
KR101987982B1 (ko) 2019-06-11
EP2486051B1 (en) 2020-03-25
JP2020000246A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
US12234272B2 (en) Pharmaceutical preparation comprising recombinant HCG
KR102108377B1 (ko) α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
CN102549011B (zh) 包含重组hcg的药物制剂
HK40020346A (en) Pharmaceutical preparation
HK1174338B (en) Pharmaceutical preparation comprising recombinant hcg
HK1174338A (en) Pharmaceutical preparation comprising recombinant hcg

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211112

Application number text: 1020217003233

Filing date: 20210201

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211209

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220308

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221012

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230111

Application number text: 1020217003233

Filing date: 20210201

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230111

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230111

End annual number: 3

Start annual number: 1

PG1601 Publication of registration